四种常见肿瘤标记物联合检测在肝胆系统良恶性疾病中的临床价值

表3 肿瘤标志物在肝胆恶性疾病疗效监测中的结果分析 (mean±SD)

指标	肝脏恶性疾病 (n = 75)		胆道恶性疾病 (n = 16)
	治疗前	治疗后	治疗前	治疗后
AFP(ng/mL)	358.03±103.17	157.37±34.161	126.37±34.38	73.93±7.832
CEA(ng/mL)	68.95±15.29	36.37±5.841	53.27±9.04	34.04±5.722
CA19-9(U/mL)	82.62±17.94	42.83±7.631	306.36±46.83	142.37±38.532
CA125(U/mL)	73.73±14.58	61.03±10.631	81.47±16.05	36.38±7.722

¹肝脏恶性疾病: 与治疗前比较, AFP: t = 17.24, P = 0.00; CEA: t = 18.19, P = 0.00; CA19-9: t = 19.83, P = 0.00; CA125: t = 7.24, P = 0.00;

²胆道恶性疾病: 与治疗前比较, AFP: t = 10.29, P = 0.00; CEA: t = 11.38, P = 0.00; CA19-9: t = 17.02, P = 0.00; CA125: t = 17.17, P = 0.00. AFP: 甲胎蛋白; CEA: 癌胚抗原; CA19-9: 糖链抗原19-9; CA125: 糖链抗原125.